

DEMO DEMO

Name: DEMO DEMO
Date of Birth: 11-12-1990
Biological Sex: Male
Age: 35
Height: 64 inches
Weight: 160 lbs
Fasting:

Telephone: 000-000-0000
Street Address:
Email:

FINAL REPORT

Accession ID: 2973500398

Provider Information

Practice Name: DEMO CLIENT, MD
Provider Name: DEMO CLIENT, MD
Phlebotomist: 0

Telephone: 000-000-0000
Address: 3521 Leonard Ct, Santa Clara, CA 95054

Report Information

● Current Result ● Previous Result | In Control | Moderate | Risk

Specimen Information

Sample Type	Collection Time	Received Time	Report	Final Report Date
Serum	2026-01-15 10:00 (PST)	2026-01-15 16:38 (PST)	Immune Zoomer - P2	2026-01-16 09:44 (PST)



3521 Leonard Ct, Santa Clara, CA 95054
1-866-364-0963 | support@vibrant-america.com | www.vibrant-wellness.com

TNP Test not performed

R&L Refer to risks and limitations at the end of report

Notes Refer to Lab notes at the end of the table

Immune Zoomer

Redefining Early Immune Detection

The Immune Zoomer is a comprehensive blood test designed to provide a deeper look into immune health beyond standard ANA or single-antibody screens. It measures over 60 autoantibodies across key systems - including gut, thyroid, pancreas, joints, skin, nervous system, eye/retina, and more - revealing hidden drivers of immune dysregulation for earlier detection and personalized prevention strategies.

It helps identify risks for conditions such as rheumatoid arthritis, Hashimoto's thyroiditis, type 1 diabetes, celiac disease, lupus, skin disorders, and systemic autoimmunity, offering actionable insights for diet, lifestyle, trigger avoidance, and treatment planning.



INTRODUCTION

Vibrant Wellness is pleased to present Immune Zoomer to support healthy lifestyle choices in consultation with your healthcare provider. The Immune Zoomer provides a semi quantitative assessment of IgG autoantibodies across multiple organ systems, including gut, thyroid, pancreas, joints, skin, nervous system, eye, blood vessels, liver, kidney, muscular system, and systemic autoimmune markers including ANA, thyroglobulin (TG), thyroid peroxidase (TPO), and high-sensitivity C-reactive protein (hsCRP). Results are intended to be interpreted by healthcare providers to guide personalized wellness strategies informed by insights into immune system activity, autoantibody presence, and systemic inflammation.


Methodology

The Immune Zoomer is a semiquantitative assay that detects IgG antibodies in human serum for the Immune Zoomer antibodies with multiplexed chemiluminescence immunoassay (CLIA) methodology. For Anti-CCP, Vibrant uses the ELISA methodology. The testing method for ANA and dsDNA is an indirect immunofluorescence assay (IFA) manufactured by EUROIMMUN and performed on the EUROPattern system. For Thyroid and Inflammation markers, Vibrant uses FDA approved Roche Cobas platform.

Interpretation of Report

The Immune Zoomer Summary provides concise information by representing the list of antigens with positive serology antibody titers that are outside the normal reference range. Reference ranges have been established using a cohort of 192 apparently healthy adults over 18 years of age, and pediatric reference ranges are not available. While the summary table provides a quick snapshot of the analytes tested, providers are encouraged to review the comments provided following the summary for a detailed description and significance of the analytes tested.

This section is followed by a complete list of all analytes tested for all antigen markers. For antibody results, the classification of Green denotes a result that is within the normal reference range, the classification of Yellow denotes a result that is moderately elevated titer with respect to the reference range and the classification of Red denotes a result that is elevated with respect to the normal reference range. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered. The reference metric, used to establish the reference range, is listed to the right of the reference range illustration (see image below) As with all testing, results should be interpreted considering a patient's history, physical examination, and/or results of other diagnostic testing.



This is followed by a complete list of all analytes tested for all antigen markers. For antibody results, the classification of Green denotes a result that is within the normal reference range, the classification of Yellow denotes a result that is moderately elevated titer with respect to the reference range and the classification of Red denotes a result that is elevated with respect to the normal reference range. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered. As with all testing, results should be interpreted considering a patient's history, physical examination, and/or results of other diagnostic testing.

Please note: It is important that you discuss any modifications to your diet, exercise, drug, and/or nutritional supplementation with your healthcare provider before making any changes. Antibody titers do not indicate the presence or absence of infection, the diagnosis of which should be made based upon a thorough evaluation of clinical history.

Immune Zoomer

Peripheral Nervous System	Current	Previous	Result	Reference
---------------------------	---------	----------	--------	-----------

Myelin-associated glycoprotein (MAG)	1.02			≤1.0
--------------------------------------	------	--	---	------

CLINICAL SIGNIFICANCE

Associated with autoimmune neuropathies

ASSOCIATED DAMAGE

Immune-mediated damage to myelin sheath of peripheral nerves, resulting in muscle weakness and sensory disturbances

SUGGESTED SUPPLEMENTS

Vitamin D: Vitamin D modulates the immune system and reduces inflammation, potentially alleviating autoimmune neuropathy symptoms.

Curcumin: Curcumin possesses strong anti-inflammatory properties that can help mitigate nerve inflammation in autoimmune neuropathy.

St. John's Wort: St. John's Wort contains compounds that may reduce nerve pain and inflammation, offering symptomatic relief in autoimmune neuropathy.

Systemic Autoimmune	Current	Previous	Result	Reference
---------------------	---------	----------	--------	-----------

















SmD2	1.19			≤1.0
------	------	--	---	------


















CLINICAL SIGNIFICANCE

Highly specific for systemic lupus erythematosus (SLE)

ASSOCIATED DAMAGE

Formation of immune complexes, contributing to tissue damage and systemic inflammation

Immune Zoomer				
Blood Vessels	Current	Previous	Result	Reference
Beta-2 Glycoprotein I (β2GPI)	0.27			≤1.0
Cardiolipin	0.51			≤1.0
Proteinase 3 (ANCA)	0.42			≤1.0
Central Nervous System	Current	Previous	Result	Reference
Myelin Basic Protein (MBP)	0.30			≤1.0
Dry Eyes and Mouth	Current	Previous	Result	Reference
SSA 52kDa	0.29			≤1.0
SSA 60kDa	0.28			≤1.0
SSB	0.40			≤1.0
α-fodrin	0.77			≤1.0
Eye	Current	Previous	Result	Reference
Aquaporin-4 (AQP4)	0.33			≤1.0
Interphotoreceptor retinoid-binding protein (IRBP, RBP3)	0.31			≤1.0
Gut	Current	Previous	Result	Reference
Parietal cell antibodies (PCA)	0.77			≤1.0
Anti S. cerevisiae antibody (ASCA)	0.64			≤1.0
Tissue transglutaminase (Anti-tTG IgG)	0.47			≤0.94
Tissue transglutaminase (Anti-tTG IgA)	0.36			≤0.94
Deaminated gliadin (Anti-DGP IgG)	0.31			≤0.94
Deaminated gliadin (Anti-DGP IgA)	0.42			≤0.94
Immune Health	Current	Previous	Result	Reference
Platelet antigens (GPIIb)	0.50			≤1.0
Platelet antigens (GPIIIa)	0.28			≤1.0





Immune Zoomer				
Immune Health	Current	Previous	Result	Reference
Interferon- α/β receptor 1	0.28			≤ 1.0
Interferon- α/β receptor 2	0.56			≤ 1.0
Joints/Arthritis	Current	Previous	Result	Reference
Collagen type II	0.69			≤ 1.0
Rheumatoid Factor (RF) (IU/mL)	<10			≤ 14.0
Citrullinated Peptide Antibodies (CCP3)	9.4			≤ 19.9
Kidney	Current	Previous	Result	Reference
α -actinin	0.42			≤ 1.0
Liver	Current	Previous	Result	Reference
Microsomal antibodies (LKM1)	0.80			≤ 1.0
Smooth muscle antibodies (ASMA)	0.37			≤ 1.0
Mixed Connective Tissue	Current	Previous	Result	Reference
U1-snRNP 68/70 kDa	0.73			≤ 1.0
U1-snRNP A	0.72			≤ 1.0
U1-snRNP C	0.48			≤ 1.0
U1-snRNP B/B'	0.42			≤ 1.0
Muscular System	Current	Previous	Result	Reference
Titin	0.27			≤ 1.0
Cardiac myosin	0.34			≤ 1.0
Jo-1 (histidyl-tRNA synthetase)	0.28			≤ 1.0
PM/Scl75	0.62			≤ 1.0
PM/Scl100	0.98			≤ 1.0

Immune Zoomer				
Pancreas	Current	Previous	Result	Reference
Insulin	0.28			≤1.0
Islet Cell Antigen 1	0.61			≤1.0
Islet Cell Antigen 2	0.30			≤1.0
Glutamic Acid Decarboxylase 65 (GAD65)	0.37			≤1.0
Glutamic Acid Decarboxylase 67 (GAD67)	0.96			≤1.0
Peripheral Nervous System	Current	Previous	Result	Reference
Ganglioside GM1	0.64			≤1.0
Myelin-associated glycoprotein (MAG)	1.02			≤1.0
Skin	Current	Previous	Result	Reference
Centromere protein (CENP A)	0.59			≤1.0
Centromere protein (CENP B)	0.32			≤1.0
Desmoglein 1	0.43			≤1.0
Desmoglein 2	0.47			≤1.0
Desmoglein 3	0.32			≤1.0
Type VII collagen	0.34			≤1.0
Scleroderma-specific antibodies (Scl-70)	0.64			≤1.0
RNA Polymerase 3	0.26			≤1.0
Systemic Autoimmune	Current	Previous	Result	Reference
Sm antigen	0.75			≤1.0
Sm/RNP	0.36			≤1.0
SmD	0.38			≤1.0
SmD1	0.55			≤1.0
SmD2	1.19			≤1.0

Patient Name: DEMO DEMO
 Date of Birth: 11-12-1990 Accession ID: 2973500398
 Service Date: 2026-01-15 10:00 (PST)

Immune Zoomer - All Markers



Immune Zoomer

Systemic Autoimmune	Current	Previous	Result	Reference
SmD3	0.65			≤1.0
Nucleosome/Chromatin	0.55			≤1.0
Histones	0.63			≤1.0
Double-stranded DNA (dsDNA) (IU/mL)	<2.6			≤99.9

Systemic Autoimmune	Current	Pattern	Titer	Previous	Pattern	Titer
---------------------	---------	---------	-------	----------	---------	-------

Antinuclear Antibodies (ANA)

Thyroid	Current	Previous	Result	Reference
---------	---------	----------	--------	-----------

Thyroglobulin (TG)	17.1			≤115.0
Thyroid Peroxidase (TPO)	<12			≤34.9

Inflammation	Current	Previous	Result	Reference
--------------	---------	----------	--------	-----------

hsCRP	0.5			≤0.9
-------	-----	--	---	------

SAMPLE

Disclaimer

Vibrant provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to these terms, you shall not access, browse, or use the report or website.

All laboratory testing is performed by Vibrant America LLC, a CLIA-certified (No. 05D2078809) and CAP-accredited (No. 8970308-01) clinical laboratory (address: 3521 Leonard Ct, Santa Clara, CA 95054). Testing is conducted only upon the order of a licensed healthcare professional. Biological specimens are collected from patients by, or at the direction of, the ordering healthcare professional.

This test is a laboratory-developed test (LDT) that has been designed, manufactured, validated and performed by Vibrant in accordance with applicable federal and state laboratory regulations. This test has not been reviewed or approved by the U.S. Food and Drug Administration (FDA). Certain individual analytes within this test may be measured using FDA-approved assays.

The informational content (including summaries, descriptions, images, and other materials) included in this report is based on publicly available scientific literature and for informational purposes only. This content and test results do not replace medical advice from a qualified healthcare professional. Test results are intended for use by healthcare professionals and must be interpreted based on their knowledge of the patient's clinical history and presentation. Any wellness, nutritional, or dietary recommendations, diagnoses of medical conditions, or treatment decisions based on these results are made at the discretion and responsibility of the healthcare professional.

Vibrant assumes no responsibility or liability arising from the use or interpretation of test results by the healthcare professional.

SAMPLE

Risk and Limitations

Results reflect biological and analytical findings at the time of specimen collection and may vary between individuals. Reference ranges for laboratory-developed tests (LDT) were established using a healthy adult population and may not be representative of other specific populations (e.g. pediatric, pregnant, individuals with chronic conditions or from all ethnic backgrounds). They do not provide absolute levels at which the symptoms may occur and hence clinical correlation by the provider is recommended.

Results may be affected by pre-analytical variables related to specimen type, collection, handling, transport, and storage. Serum specimens may be impacted by factors such as hemolysis, lipemia, icterus, clotting, insufficient sample volume, delayed shipment, or improper storage conditions. Serum results may also vary depending on clotting time, centrifugation parameters, and time to separation. Degradation or instability of certain analytes may occur if specimens are not collected, processed, or shipped according to recommended guidelines, potentially affecting result accuracy or leading to a Test Not Performed (TNP). In some TNP cases, repeat testing may be recommended when clinically appropriate, although repeat testing may still not yield a reportable result if the underlying limitations persist.

Results generated using laboratory testing methodologies are subject to inherent analytical limitations related to instrument performance, assay specifications of individual FDA-approved and laboratory-developed test (LDT) analytes included in the test panel, and methodological variability. As with all clinical laboratory testing, there is a small chance that the laboratory could report incorrect results.

The reported analytes and associated informational content are informed by scientific knowledge at the time of reporting, including peer-reviewed scientific publications, publicly available research, and guidance from recognized scientific and public health organizations. Interpretive content may be updated as scientific knowledge continues to evolve.

Vibrant does not diagnose, treat, or cure medical conditions and does not replace the care of a licensed medical practitioner or counselor, nor does Vibrant recommend self-diagnosis or self-medication. Depending on the nature of testing, individuals who receive moderate- or high-risk results may be advised to pursue confirmatory testing and appropriate medical follow-up. Vibrant assumes no liability for any loss, injury, or damages arising from the procurement, compilation, interpretation, delivery, or reporting of information contained in this report, nor from any decisions made or actions taken based on these results.

The supplement recommendations and dosage guidelines provided are intended for general informational purposes only and should not replace professional medical advice; final dosage decisions must be made in consultation with your healthcare provider. Vibrant disclaims any liability for adverse effects, outcomes, or consequences arising from the use of these suggestions.